Obermatt
See Similar Stocks →

Surrozen

NAQ:SRZN · US86889P2083
BiotechnologySmall

360

33
Profit price11
Owner Earnings Yield1
Dividend Yield1
Price/Sales25
Price/Book82
Returns on capital97
Profit margins37
Accruals100
Owner Earnings Margin10
Sales growth82
Profit growth82
Reinvestment73
Price momentum73
Debt load70
Refinancing79
Debt Payback1
Liquidity42
Analyst ratings100
Opinion Changes50
Price Target Upside36
Market mood35
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Surrozen doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees67
Websitesurrozen.com
ISINUS86889P2083
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyOphthalmologyNeurologyInflammationCentral Nervous SystemHepatologyBiotechnologyEmergency MedicineHealth Care

Description

Surrozen, Inc. (Surrozen) operates as a clinical-stage biotechnology company. The company is discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tiss…

Analysis

Hope premium

Surrozen, Inc. is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.

Valuation data is not available for this company.

Growth is solid; the safety picture is stretched. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
91
2026

All-time high

98

Mar 2026

All-time low

91

Jun 2026

Average rank

95

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
25
—
—
—
Price/Earnings
33
—
—
—
Price/Book
82
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
31
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Surrozen with its peers
Apellis Pharmaceuticals
NSQ:APLS
75
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Nuvectis Pharma
NAQ:NVCT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MacroGenics
NSQ:MGNX
24
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kodiak Sciences
NMQ:KOD
82
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
NovaBridge Biosciences
NMQ:NBP
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tenaya Therapeutics
NSQ:TNYA
29
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →